Schwarzenegger Discusses Executive Action to Strengthen Stem Cell Research in Press Conference Friday GOVERNOR SCHWARZENEGGER:
Good morning, everybody. Good morning. Yesterday I directed my Department of Finance to loan up to 150 million dollars to the California Institute for Regenerative Medicine. The court’s affirmative decision a few months ago in the Proposition 71 challenge leads me to believe that there’s no reason why we should not go and make this money available as soon as possible. I’m 100 percent committed to advancing stem cell research in California, and to the promise that it holds for millions of our citizens who suffer from chronic diseases. California is poised to lead not only the state but the country, and all countries, on stem cell research. We cannot fall behind other nations that make this life-saving science their priority. I believe it is critical that we take action to ensure continued progress of this revolutionary science. This is another opportunity of the people of California to lead the way.
Thank you. And now I would like to have my friend Bob Klein, who is actually the man that has led Proposition 71 to victory, come out and say a few words. Please.
posted
looks like Barchart made some changes in our favor
Composite Indicator -- Signal -- -- Strength -- -- Direction -- Trend Spotter (TM) Hold Bullish
Short Term Indicators 7 Day Average Directional Indicator Buy Minimum Strengthening 10 - 8 Day Moving Average Hilo Channel Buy Minimum Weakening 20 Day Moving Average vs Price Buy Minimum Strongest 20 - 50 Day MACD Oscillator Buy Average Weakest 20 Day Bollinger Bands Hold Bullish
Short Term Indicators Average: 80% - Buy
Medium Term Indicators 40 Day Commodity Channel Index Hold Bullish 50 Day Moving Average vs Price Buy Weak Strongest 20 - 100 Day MACD Oscillator Buy Minimum Weakening 50 Day Parabolic Time/Price Buy Average Strongest
Medium Term Indicators Average: 75% - Buy
Long Term Indicators 60 Day Commodity Channel Index Hold Rising 100 Day Moving Average vs Price Buy Minimum Strongest 50 - 100 Day MACD Oscillator Sell Minimum Weakest
posted
Originally Posted by miagiovni e mail sent from another board: Email-Sent to Governor Arnold....Ca. The Governor, Arnold, A company that stores stem cells,located in Irvine California Name...Calbatech,Inc. Would it not be great to show your belief in the research and storage. By having you the first Governors of our USA, state.Be the first to store his adult stem cell,with the world media looking on.
Make everyone in our country a believer in the research..
This is already being done and approved in Europe, Lets not loose our good researchers to Europe,or other continents. Keep the in the USA.
Governor Arnold Be bold, and Be THE FIRST..!!! Thank You,
It is the Company's intention to protect its proprietary property through the filing of U.S. and international patent applications, both broad and specific, where necessary and reasonable. The Company believes it will attain strong and broad patent protection for its technologies. It is the Company's intention that all its products be protected under various pending patents, issued patents, copyrights and trademarks.
The Company has the policy of disclosing its proprietary information only under a Confidentiality Agreement. This Agreement has a special clause regarding ownership by the Company of all inventions related to, or based in any way upon, the Company's technologies.
The Company expects to experience growth in the number of employees relative to its current levels of employment and the scope of its operations. In particular, the Company may need to hire scientists, as well as sales, marketing and administrative personnel. Additionally, acquisitions could result in an increase in employee headcount and business activity. Such activities could result in increased responsibilities for management. The Company believes that its ability to attract, train, and retain qualified technical, sales, marketing, and management personnel, will be a critical factor to its future success. During strong business cycles, the Company may experience difficulty in filling its needs for qualified personnel.
Our future performance and success are dependant upon the efforts and abilities of our Management. To a very significant degree, we are dependent upon the continued services of James DeOlden, Edward Deese and John Gordon, our founders and Directors. If we lost the services of Mr. DeOlden, Mr. Deese or Dr. Gordon or other key employees before we could get a qualified replacement, that loss could materially adversely affect our business. We currently maintain key man life insurance on the lives of Mr. DeOlden and Mr. Deese in the amounts of $3,000,000 and $2,842,000 respectively.
posted
the 10-Q is fair and shows absolutley no dilution from previous quarter which is great.The stem cell banking revs will be in Q-3 of course but as the CEO stated,CLBE will be profitable in 06 and they are surely on track. I figure we get a PR early tomorrow on the opening of the stem cell banking system.
one thing everyone can say...CLBE surely came thru and filed on time!!
LifeStem anticipates launching its Stem Cell MircoBank Service on August 15th, 2006. LifeStem has initially concentrated on medspa locations in Southern California. At a recent meeting of all of the current Solana Medspas, a large number of the medspas outside of California expressed enthusiasm as to being able to carry LifeStem's service outside of California and LifeStem is working to make that happen more rapidly than originally anticipated. As such, the Stem Cell MicroBank Service will be initially rolled out in California and then quickly move to other states such as Florida, New York and North Carolina. LifeStem is projecting $3,858,000 in revenues in the first twelve months of operation and $26,275,000 during the second twelve months of operation.
posted
this now shows that this company mean business and every segment compliments each other.I will surely hold a core position here for quite a while,the long term value imo will definitely be in the dollars.
quote:Originally posted by QuestSolver: FINANCIAL PROJECTIONS
LifeStem anticipates launching its Stem Cell MircoBank Service on August 15th, 2006. LifeStem has initially concentrated on medspa locations in Southern California. At a recent meeting of all of the current Solana Medspas, a large number of the medspas outside of California expressed enthusiasm as to being able to carry LifeStem's service outside of California and LifeStem is working to make that happen more rapidly than originally anticipated. As such, the Stem Cell MicroBank Service will be initially rolled out in California and then quickly move to other states such as Florida, New York and North Carolina. LifeStem is projecting $3,858,000 in revenues in the first twelve months of operation and $26,275,000 during the second twelve months of operation.
and your estimate of PPS based on these numbers is ...
Posts: 1580 | From: World | Registered: Jul 2006
| IP: Logged |
posted
considering how many microbank openings are expected before year end not to mention the ones Calbatech is in partnerships with such as Solena I still believe the PPS could close the year out at or near .50's or even higher.Watch for news sometime today on the opening of the fist in CA.
posted
CORPORATE MISSION AND OBJECTIVES In order to accomplish its goals, CalbaTech is pursuing a strategy of combining products and technologies, and the companies that provide them, into the following divisions: 1) Molecular Applications; 2) Research Reagents; and 3) Cellular Therapeutics. By pursuing such a strategy, each division should produce value added and increasing returns on shareholders' investment through cross marketing of products and geographic expansion, as well as to achieve product enhancement and efficiency KD MEDICAL, INC. CalbaTech acquired KD in the last quarter of 2004. This acquisition substantially increased both product range and revenue in the Research Reagents Division. The product ranges of KD and Molecula are highly complementary, with little over lap. A strength of KD is in the supply of specialized media for culture of model research organisms such as bacteria, yeast, insects and mammalian cell lines. It also supplies products to approximately 300 National Institutes of Health ("NIH") laboratories, contracts invaluable for establishing new products in a favorable government setting. Its secondary products are related to molecular biology reagents. Conversely, Molecula's primary focus is in the design and supply of high value molecular biology reagents such as siRNA and DNA antisense oligonucleotides. It also has reagents such as IPTG that are complementary to customized media. KD believes that the addition of new product lines could significantly increase its revenues within the NIH, to as much as $5 Million annually, within the next five years. A large proportion of molecular biology research depends upon culture of a model organism (bacteria, fruit fly, etc.), which is genetically manipulated by transfection of customized oligonucleotides (siRNA). Thus, an alliance of KD and Molecula will be well placed to provide a competitive single source for these culture media transfection reagents and specialized modifier molecules such as siRNA. Further, as explained above, KD's long standing and trusted position, as a major in-house supplier to NIH will greatly ease entry of Molecula's siRNA into that major market. Please see www.kdmedical.com. CUSTOMERS KD Medical and Molecula service five distinct customer types: 1) Federally funded research centers such as the National Institutes of Health, the Naval Medical Center, and the National Cancer Institute; 2)Federally funded "Supply Stores" such as at the National Institutes of Health; 3) University and private research centers such as Glaxo Smith-Kline, Johnson & Johnson, Merck & Co., Pfizer Research, and Wyeth Pharmaceuticals; 4) Medical distributors such as Fisher Scientific and VWR International; and 5) OEMs such as Genetix, Ltd. and PML Microbiologicals, Inc. MARKET SIZE The general laboratory supplies industry is 12 to $14 Billion, and the molecular biology market to which the Company provides products and services for medical research and drug discovery on which billions of dollars are spent each year. Specifically, the molecular biology market is approximately $600 Million per year, and the RNAi market is estimated to be $328 Million by 2010. FINANCIAL PROJECTIONS The Reagents Division has two companies with combined 2005 revenues of approximately $1.225 Million in gross revenues. CalbaTech believes that combined revenues within the division will be $1.5 Million in 2006. Within three years, it is anticipated that revenues will grow to $5 Million. PATENTS AND PROPRIETARY TECHNOLOGY It is the Company's intention to protect its proprietary property through the filing of U.S. and international patent applications, both broad and specific, where necessary and reasonable. The Company believes it will attain strong and broad patent protection for its technologies. It is the Company's intention that all its products be protected under various pending patents, issued patents, copyrights and trademarks. The Company has the policy of disclosing its proprietary information only under a Confidentiality Agreement. This Agreement has a special clause regarding ownership by the Company of all inventions related to, or based in any way upon, the Company's technologies.
posted
CalbaTech Announces Six Month Revenues; LifeStem, Initially in California, Expects to Launch Service in Florida, New York, North Carolina and Other States in the Near Term 8/15/2006
IRVINE, Calif., Aug 15, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com ) concentrating on providing products and platforms to the biotech and pharmaceutical research market and to academic institutions, and banking of adult stem cells for possible future therapeutic uses, today announced its second quarter financial results.
Revenues for the first six months of 2006 totaled $655,122, up five percent from the same period in 2005. Revenues were down slightly in the second quarter, dropping from $310,525 in 2005 to $242,558 in 2006 because of down time while the Company moved two subsidiaries into a new facility. Gross profit increased and totaled $205,377 in the second quarter of 2006 compared to $129,665 in 2005. Accounting for derivative liability recognition caused the company to achieve net revenues of approximately $13,000 for the six-month period, as compared to a loss of approximately $2.2 million for the same period in 2005.
The Company also announced that LifeStem, its wholly owned subsidiary, presented its Stem Cell MicroBank(TM) Service at a national convention of medspa owners and anticipates launching its MicroBank(TM) Service in Florida, New York, North Carolina and other states soon after the August 15th, 2006, California launch date. LifeStem is projecting $3.9 million in revenues in the first twelve months of operating the nation's first service to collect micro-quantities of adult stem cells from multiple tissue sources for future potential therapeutic use.
James DeOlden, CalbaTech CEO, said the Company anticipates that revenues will increase throughout the balance of 2006, not only due to launching LifeStem's Stem Cell Microbank(TM) Collection Service, but also due to two subsidiaries, Molecula, Inc. and KD Medical, Inc., having combined operations to be more efficient and having moved into a new facility that should increase quality and improve manufacturing capabilities.
-------------------- ......in Psychiatry circles it's known as a "warning sign" Posts: 1736 | From: Saint Louis | Registered: Jul 2005
| IP: Logged |
posted
yes but DT's are creatures of habit and pretty much always sell on the financials whether they are good or not the first hour of today is going to be a roller coaster ride so I advise to just sit back and watch it
Solana MedSpas, the nation’s foremost developer and syndicator of medical spas, has signed an agreement with LifeStem, Inc. to offer their unique Stem Cell MicroBank Service through the Solana MedSpas network. The announcement was made by John Buckingham, CEO and co-founder of Irvine, Calif.- based Solana MedSpas. LifeStem, Inc. is a wholly owned subsidiary of CalbaTech, Inc. (OTC Bulletin Board: CLBE), a publicly traded emerging life sciences company concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
“We are delighted to finalize our partnership with LifeStem,” Buckingham says, noting that Solana MedSpas will be the first medspa network to offer an adult stem cell collection service. “As Solana MedSpas continues to orchestrate the marriage of healthcare product innovation with our ever expanding medspa distribution channel, we are moving beyond aesthetic treatments to become a provider of medical services in a broader sense.” Solana MedSpas expects to have as many as 70 locations open by the end of 2006 and intends to offer the Stem Cell Microbank Service at key locations.
“We are extremely pleased that we have formalized an agreement with Solana MedSpas,” says LifeStem president Dan Fulkerson, “and are confident that many individuals within the Solana MedSpas client base will take advantage of our Stem Cell MicroBank™ service.” “By beginning with six locations and adding new outlets as Solana MedSpas debuts them, our conservative estimates project revenues in excess of $3 million over the first 12 months of operations with the potential to exceed $25 million in the next couple of years,” Fulkerson notes.
Recent research indicates that autologous (one’s own) adult stem cells provide advantages similar to embryonic stem cells without ethical controversy or the risk of rejection. Current scientific data supports the fact that adult stem cells hold the potential for treatment, cure and possible prevention of numerous afflictions such as heart disease, Parkinson’s Disease, diabetes, Alzheimer’s disease, and spinal cord injuries. Other possible benefits include regeneration of cardiac tissue after heart attack, regeneration of joint surfaces to reverse the ravages of osteoarthritis and joint disease, augmentation of the body’s ability to heal after elective surgeries to improve healing and speed recovery, and boosting of the immune system’s ability to fight infection and even cancer.
About Solana MedSpas Founded in July 2003, Solana MedSpas is the nation’s innovative leader in the development and syndication of medical spas. Solana MedSpas has created a new market segment by orchestrating the marriage of healthcare innovation with its ever expanding medspa distribution channel, making its proprietary content simultaneously available to its growing distribution network of uniquely branded medical spa facilities all over North America. Moving beyond aesthetic medical treatments, Solana MedSpas is the nation’s first medspa network to offer a broader range of medical treatments in a retail spa environment. Solana Medspas provides the industry's only model for a legally compliant, competitive, and forward-thinking business in all 50 states.
About LifeStem LifeStem, Inc. a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of “Cellular Logistics.” The Company’s focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications, and clinical applications of specific stem cell based therapies. LifeStem, in addition to being the first company to offer micro collection of stem cells,is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device and its novel Stem Cell MicroBank service.
About CalbaTech CalbaTech, Inc. (OTC Bulletin Board: CLBE ) is an emerging life sciences company, concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
posted
LifeStem, in addition to being the first company to offer micro collection of stem cells,is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device and its novel Stem Cell MicroBank service.
quote:Originally posted by maxdog: I really thought this would be a good day for us, not starting out so great.
It seems the last few big runs I have been in, the MMs hold it down and even drop it after good news. They collect a lot of shares are people sell. Then the next day or two they run the crap out of it. See IGAI for an example. The 10Q came out the PPS dropped. Then next day it dropped big time to 0.0034, then 3rd day BOOM to almost 6 cents.
I'm not saying it will have an IGAI run, but it just seems thats what the MMs are doing these days.
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes. Posts: 1450 | From: TX | Registered: Feb 2006
| IP: Logged |
posted
this is a company right on track that they didn't even need to increase the OS in 2 quarters and thats still under 100 mill with 25% of those locked up by insiders....so that tells me they are pretty much self supportive right now.
posted
Squire, I certainly hope your correct, a nice little run is in order now after this close.
Posts: 37 | From: Wyoming | Registered: Jul 2005
| IP: Logged |
posted
It keeps on doing this, going up just a bit, and then dropping back down. I am still negative for when I bought three weeks ago. Its been "next week" for about a month.
Posts: 17 | Registered: Jul 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
